Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
Tuesday, July 25, 2017 - 21:22
in Mathematics & Economics
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.